FBLG
FibroBiologics, Inc.
$0.84
-0.01 (-0.60%)
At close · Jul 17
Going-concern doubt
— flagged Apr 30, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the condensed consolidated financial statements. While management has implemented plans to obtain additional funding, these plans are not sufficient to alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Apr 30, 2026
Market Cap
$4.35M
Shares
5,208,915
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.84
Open$0.82
Day$0.80–0.85
52W$0.73–14.68
Avg vol 30d153K
Short int136K · 2.6% float · 1.0d
Short vol70%
DataJan 2024–Jul 2026
Filing10-Q · Apr 30
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 30, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.8 · elevated
Equity put/call 0.73
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−82%
below
Price vs 50-day avg
−13%
below
RSI (14)
43
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+4%
trailing
6-month return
−90%
trailing
YTD return
−81%
this year
Relative strength
−97%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-70% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.61% of float · ▼ -0.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
14 holders — near 2-yr low, contrarian setup
Squeeze score
44
elevated · 0–100
Fundamentals
EPS growth
−24%
Y/Y
Free cash flow
$-16.7M
Balance sheet
$4.9M
net cash
Quant / Vol
risk profile
Volatility
124%
annualized · 1-yr
Max drawdown
−95%
past year
ATR
9.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−82%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
43
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $5 — 200d above 50d
Institutional flow
Distributing
-70% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.61% of float · ▼ -0.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
14 holders — near 2-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $1
Now $1 · 1%
52-wk high $15
vs 200-day avg -82%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FBLG
this stock
FibroBiologics, Inc.
|
$4.35M | -81.4% | — | — | 2.6% |
|
ONC
BeOne Medicines Ltd.
|
$450.95B | +2.7% | +22179.2% | 917.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.26B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.94B | -12.2% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$53.84B | +2.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FBLG | -8.9% | +4.4% | -89.6% | -11.9% | -81.4% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | -7.4% | +4.1% | -97.4% | -11.5% | -90.4% |